“If approved, Ajovy could be an important step toward filling the gap in pediatric migraine care, offering a much-needed solution for this underserved population.” Ajovy is supplied in both a ...

If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in ...

Teva (TEVA) Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application for AJOVY to expand the indication to include the ...

Teva Pharmaceutical Industries recently received FDA acceptance of its supplemental Biologics License Application to expand AJOVY®'s use for preventing migraines in pediatric patients ...

If approved, AJOVY would be the only calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, helping to address ...

If approved, AJOVY would be the only calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, helping to address ...